RxDoctor Payments DataLook up a doctor →

Juan Carlos Rondon, MD

Internal Medicine · Hollywood, FLNPI 1245284181

Payments from drug & device makers

$66,802,405in general payments, 2019–2025

Across 1,570 payments — averaging $42,549 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Mylan Pharmaceuticals Inc.$17.6M
  • Eli Lilly$8.6M
  • AbbVie$6.2M
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$5.4M
  • Genentech, Inc.$4.6M
  • Merck$3.4M
  • plus $20.9M from 47 others
$47,521in research payments, 2019–2025

Across 15 payments — averaging $3168.08 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$46K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$2K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Mylan Pharmaceuticals Inc.235$17,588,819
Eli Lilly20$8,599,179
AbbVie76$6,221,369
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)91$5,446,997
Genentech, Inc.74$4,599,469
Merck55$3,428,108
Bayer81$2,505,050
Myovant Sciences GmbH18$2,179,734
Takeda Pharmaceuticals U.S.A., Inc.49$1,708,919
Tris Pharma Inc13$1,645,065
Sumitomo Pharma America, Inc.66$1,583,662
Regeneron12$1,135,505
E.r. Squibb & Sons, L.L.C.13$1,017,322
Vertex3$893,283
Astrazeneca UK Limited14$790,889
Sanofi28$704,097
Endo Pharmaceuticals Inc.66$700,072
Mallinckrodt LLC8$694,230
Sanofi US Services Inc.22$666,885
Gilead46$577,679
Evofem Biosciences, Inc.36$459,937
Amgen11$444,755
Incyte Corporation44$401,965
AstraZeneca4$353,384
Siemens Medical Solutions USA, Inc.18$326,248
Pfizer18$248,735
Mylan Technologies Inc.5$217,095
F. Hoffmann-la Roche AG13$215,612
Taiho Oncology, Inc.14$202,685
Sunovion Pharmaceuticals Inc.185$186,311
Principia Biopharma Inc.11$179,034
Agios Pharmaceuticals, Inc.4$170,487
Hexal AG5$168,644
Bausch Health US, LLC47$119,976
Biontech SE17$90,619
Astellas Pharma Inc16$74,640
Sage Therapeutics, LLC1$73,805
Ipsen Bioscience Inc.11$68,748
Novartis7$43,260
Otsuka Pharmaceutical Development & Commercialization, Inc.3$29,819
Boehringer Ingelheim International GmbH6$22,604
Boehringer Ingelheim Pharma GmbH & Co.kg66$8,751
Avanir Pharmaceuticals, Inc.2$8,000
Viiv Healthcare Company19$354
GSK2$125
CSL Behring1$104
Mallinckrodt Hospital Products Inc.3$80
Sun Pharmaceutical Industries Inc.1$80
EMD Serono, Inc.3$75
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC3$60
Amarin Pharma, Inc.2$38
Organogenesis Inc.1$24
Orapharma, A Division Of Bausch Health US, LLC1$18

How this compares

$66,802,405 in reported general payments places this provider in the 95th percentile of 8,530 internal medicine providers in Florida.

See all internal medicine providers in Florida →

Medicare billing

Part B allowed, 2024
$13,439
Medicare patients
22
Services billed
654

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other internal medicine in Hollywood

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →